Skip to main content
SpringerLink
Log in

Experience in the Use of Valdoxan in the Treatment of Post-Stroke Depression

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Valdoxan at a dose of 25 mg per day for three months was used in 40 patients aged 55–85 years with post-stroke depression. Patients’ status was assessed clinically and in terms of a series of scales (Hamilton, MMSE, Tinnetti, etc.). High antidepressant efficacy and good tolerance were demonstrated. On the background of stabilization of the emotional background, patients showed improvements in motor and cognitive functions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. B. A. Volel, “Valdoxan (agomelatine): an innovatory mechanism of action,” Psikhiatr. Psikhofarmakoter., 3, 35–39 (2008).

    Google Scholar 

  2. E. I. Gusev, A. B. Gekht, A. N. Bogolepova, and I. B. Sorokina, “Characteristics of depressive syndrome in patients with ischemic stroke,” Zh. Nevrol. Psikhiat., Stroke Suppl., 3, 28–31 (2001).

    Google Scholar 

  3. E. I. Gusev and A. N. Bogolepova, “Depressive disorders in stroke patients,” Zh. Nevrol. Psikhiat., Stroke Suppl., 22, 10–16 (2008).

    Google Scholar 

  4. S. V. Ivanov, “Valdoxan (agomelatine) in the treatment of moderate and severe nonpsychotic depression in out-patient and hospital practice (results of the Russian Multicenter Study CHRONOS),” Psikhiatr. Psikhofarmakoter., 6, 14–17 (2009).

    Google Scholar 

  5. “A set of measures for the prophylaxis, diagnosis, and treatment of patients with cardiovascular diseases in the Russian Federation. Federal Program [in Russian],” in: Proc. 2nd Russ. Int. Congr. Cerebrovascular Pathology and Stroke, Vol. 7, p. 20 (2007).

  6. V. E. Medvedev, “Perspectives in the use of melatoninergic agents in the treatment of depression in patients with cardiovascular diseases,” Psikhiatr. Psikhofarmakoter., 3, 17–22 (2010).

    Google Scholar 

  7. V. E. Medvedev and A. V. Epifanov, “An innovatory method for the treatment of depression in patients with ischemic heart disease,” Oboz. Psikhiatr. Med. Psikhol. im. Bekhtereva, 3, 31–36 (2010).

    Google Scholar 

  8. V. I. Skvortsova, “Decreases in the morbidity, lethality, and disability due to stroke in the Russian Federation,” Zh. Nevrol. Psikhiat., Stroke Suppl., Spec. Iss., Proc. 2nd Russ. Int. Congr. Cerebrovascular Pathology and Stroke, 25–27 (2007).

  9. A. B. Smulevich and S. V. Ivanov, “Depression and biological rhythms: the CIRCADIAN-1 questionnaire study,” Psikhiatr. Psikhofarmakoter., 6, 4–8 (2008).

    Google Scholar 

  10. L. I. Syromyatnikova, T. A. Spigina, and V. V. Shestakov, “Circadian rhythm and depression in cardiological patients,” Psikhich. Rasstr. Obshch. Med., 1, 19–24 (2010).

    Google Scholar 

  11. A. Berg, H. Palomäki, M. Lehtihalmes, et al., “Poststroke depression: an 18-month follow-up,” Stroke, 34, 138–143 (2003).

    Article  PubMed  Google Scholar 

  12. A. Berg, J. Lonnqvist, H. Palomaki, and M. Kaste, “Assessment of depression after stroke. A comparison of different screening instruments,” Stroke, 40, 523–529 (2009).

    Article  PubMed  Google Scholar 

  13. M. Bourin, E. Mocaër, and R. Porsholt, “Antidepressant-like activity of S20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors,” J. Psych. Neurosci., 29, No. 2, 126–133 (2004).

    Google Scholar 

  14. D. Eser, T. C. Baghai, and H.-J. Möller, “Agomelatine: the evidence for its place in the treatment of depression,” Core Evidence, 3, 171–179 (2009).

    Article  Google Scholar 

  15. G. M. Goodwin, F. Rouillon, and R. Emsley, “Long-term treatment with agomelatine: prevention of relapse in patients with major depressive disorder over 10 months (abstract),” 21st European College of Neuropsychopharmacology Congress, Aug. 30 – Sept. 3, 2008, Barcelona, Spain, Eur. Neuropsychopharmacol., 18, 338–339 (2008).

    Article  Google Scholar 

  16. C. Haacke, A. Althous, A. Spottke, et al., “Long-term outcome after stroke evaluating health-related quality of life using utility measurements,” Stroke, 37, 193–198 (2006).

    Article  PubMed  Google Scholar 

  17. M. J. Joliat, M. E. Schmidt, M. Fava, et al., “Long-term treatment outcomes of depression with associated anxiety – efficacy of continuation treatment with fluoxetine,” J. Clin. Psychiatry, 65, 373–378 (2004).

    Article  PubMed  CAS  Google Scholar 

  18. B. S. Jonas and J. F. Lando, “Negative affect as a prospective risk factor for hypertension,” Psychosom. Med., 62, 188–196 (2000).

    PubMed  CAS  Google Scholar 

  19. M. Lader, “Pharmacotherapy of mood disorders and treatment discontinuation,” Drugs, 67, 1657–1663 (2007).

    Article  PubMed  CAS  Google Scholar 

  20. T. Lindén, C. Blomstrand, and I. Skoog, “Depressive disorders after 20 months in elderly stroke patients: a case-controlled study,” Stroke, 38, 1860–1863 (2007).

    Article  PubMed  Google Scholar 

  21. R. S. K. Lo, J. O. Y. Cheng, E. M. C. Wong, et al., “Handicap and its determinants of change in stroke survivors: one-year follow-up study,” Stroke, 39, 148–153 (2008).

    Article  PubMed  Google Scholar 

  22. H. Loo, A. Hale, and H. D’haenen, “Determination of the Valdoxan dose, a melatoninergic agonist and selective 5-HT2c antagonist, in the treatment of major depressive disorder: a double-blind, placebocontrolled study with dose ranging (abstract),” Psikhiatr. Psikhofarmakoter., 2, 52–58 (2009).

    Google Scholar 

  23. S. D. Mendelson, “The current status of the platelet 5-HT receptor in depression,” J. Affect. Disord., 57, 13–24 (2002).

    Article  Google Scholar 

  24. M. J. Millan, A. Gobert, F. Lejeune, et al., “The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways,” J. Pharmacol. Exp. Ther., 306, 954–964 (2003).

    Article  PubMed  CAS  Google Scholar 

  25. S. A. Montgomery, S. H. Kennedy, G. D. Burrows, et al., “Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, doubleblind, placebo-controlled discontinuation study,” Int. Clin. Psychopharmacol., 19, 271–280 (2004).

    Article  PubMed  CAS  Google Scholar 

  26. S. A. Montgomery, J.-P. Oli, and S. H. Kennedy, “Antidepressant efficacy of agomelatine in major depressive disorder: meta-analysis of three pivotal studies,” Eur. Neuropsychopharmacol., 16, Suppl. 4, 321 (2006).

    Article  Google Scholar 

  27. V. Murray, M. Von Arbin, A. Bartfai, et al., “Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression,” J. Clin. Psychiatry, 66, 708–716 (2005).

    Article  PubMed  CAS  Google Scholar 

  28. D. L. Musselman, E. Betan, H. Larsen, and L. S. Phillips, “Relationship of depression to diabetes mellitus types 1 and 2: epidemiology, biology, and treatment,” Biol. Psychiatry, 54, 317–329 (2003).

    Article  PubMed  Google Scholar 

  29. K. Narushima, J. T. Kosier, and R. G. Robinson, “A reappraisal of poststroke depression, intra- and inter-hemispheric lesion location using meta-analysis,” J. Neuropsych. Clin. Neurosci., 15, 422–430 (2003).

    Article  CAS  Google Scholar 

  30. J. H. Pan, X. Y. Song, S. Y. Lee, et al., “Longitudinal analysis of quality of life for stroke survivors using latent curve models,” Stroke, 39, 2795–2802 (2008).

    Article  PubMed  Google Scholar 

  31. S. L. Paul, H. M. Dewey, J. W. Sturm, et al., “Prevalence of depression and use of antidepressant medication at 5 years poststroke in the North East Melbourne Stroke Incidence Study,” Stroke, 37, 2854–2855 (2006).

    Article  PubMed  CAS  Google Scholar 

  32. M. A. Quera Salva, B. Vanier, J. Laredo, et al., “Major depressive disorder, sleep EEG and agomelatine: an open-label study,” Int. J. Neuropsychopharmacol., 10, 691–696 (2007).

    PubMed  CAS  Google Scholar 

  33. R. G. Ronbins, G. Spalleta, R. E. Jorge, et al., “Decreased heart rate variability is associated with poststroke depression,” Am. J. Geriatr. Psychiatry, 16, No. 11, 867–873 (2008).

    Article  Google Scholar 

  34. M. Santos, G. Gold, E. Kowari, et al., “Differential impact of lacunes and microvascular lesions on poststroke depression,” Stroke, 40, 3557–3562 (2009).

    Article  PubMed  Google Scholar 

  35. J. W. Sturm, G. A. Donnan, H. M. Dewey, et al., “Determinants of handicap after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS),” Stroke, 35, 715–720 (2004).

    Article  PubMed  Google Scholar 

  36. R. Vataja, A.Leppävuori, T. Pohjasvaara, et al., “Poststroke depression and lesion location revisited,” J. Neuropsych. Clin. Neurosci., 16, 156–162 (2004).

    Article  CAS  Google Scholar 

  37. S. Wassertheil-Smoller, W. B. Applegate, K. Berge, et al., “Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the Elderly),” Arch. Int. Med., 5, 553–561 (1996).

    Article  Google Scholar 

  38. E. M. Whyte, B. H. Mulsant, J. Vanderbilt, et al., “Depression after stroke: a prospective epidemiology study,” J. Am. Geriatr. Soc., 52, 774–778 (2004).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology and Neurosurgery, Therapeutic Faculty, N. I. Pirogov Russian State Medical University, Russian Ministry of Health, Moscow, Russia

    A. N. Bogolepova, E. I. Chukanova, M. Yu. Smirnova, A. S. Chukanova, I. Yu. Gracheva & E. G. Semushkina

Authors
  1. A. N. Bogolepova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. I. Chukanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Yu. Smirnova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. S. Chukanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Yu. Gracheva
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. G. Semushkina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. N. Bogolepova.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 111, No. 4, pp. 42–46, April, 2011.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bogolepova, A.N., Chukanova, E.I., Smirnova, M.Y. et al. Experience in the Use of Valdoxan in the Treatment of Post-Stroke Depression. Neurosci Behav Physi 42, 556–560 (2012). https://doi.org/10.1007/s11055-012-9600-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-012-9600-4

Keywords

Search

Navigation